Royalty Pharma CFO Sells Company Shares Worth Billions

On April 1 and April 28, 2026, Royalty Pharma plc’s Chief Financial Officer Terrence P. Coyne sold shares of Class A common stock in the market on two occasions under a pre-established Rule 10b5-1 trading plan. Each sale amounted to approximately $1.7 million (about 2 billion Korean won apiece), for a total of roughly $3.4 million (around 4 billion won). Coyne still retains a significant economic interest in the company through accounts held in his and his family’s names, convertible partnership interests, and shares subject to vesting.

The company’s stock has shown strength recently, reaching a 52-week intraday high of $50.24 on April 28. Royalty Pharma has also announced that it will release its first-quarter 2026 financial results before the U.S. market opens on May 6.

Founded in 1996, Royalty Pharma is a New York–based financial firm specializing in biopharmaceutical royalties. Its business model provides non-dilutive capital to drug developers and rights holders in exchange for future royalties on approved and late-stage products. Listed on Nasdaq, the company has a market capitalization of approximately $26 billion (about 34 trillion Korean won).